Jessica McCluskey, MD
Ophthalmology · Sandy Springs, GANPI 1447352604
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (55.3%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. Alimera Sciences, Inc. accounts for 77.5% of it on its own, with 19 other manufacturers making up the rest. Reporting peaked in 2019 at $14,932 and has fallen 97.4% since, to $390 in 2025. Among ophthalmology clinicians in GA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 132 payments — averaging $171.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alimera Sciences, Inc.$18K
- Eyepoint US, Inc.$2K
- Genentech USA, Inc.$652
- Coopervision Inc.$500
- AbbVie$420
- Regeneron Healthcare Solutions, Inc.$354
- plus $2K from 14 others
What the payments were for
- Consulting fees$4,12018%
- Speaking & faculty fees$12,50055%
- Travel & lodging$1,9999%
- Food & beverage$3,48315%
- Education$5002%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alimera Sciences, Inc. | 32 | $17,510 |
| Eyepoint US, Inc. | 3 | $1,643 |
| Genentech USA, Inc. | 16 | $652 |
| Coopervision Inc. | 2 | $500 |
| AbbVie(2 entities) | 14 | $420 |
| Regeneron Healthcare Solutions, Inc. | 14 | $354 |
| Apellis Pharmaceuticals, Inc. | 11 | $258 |
| Carl Zeiss Meditec, Inc. | 2 | $252 |
| Alcon | 6 | $239 |
| Novartis | 8 | $232 |
| Sun Pharmaceutical Industries Inc. | 6 | $123 |
| Astellas Pharma US Inc | 5 | $109 |
| ANI Pharmaceuticals, Inc. | 4 | $78 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $55 |
| Sandoz | 2 | $53 |
| Harrow Eye, LLC | 2 | $34 |
| Dutch Ophthalmic, USA | 1 | $32 |
| Tarsus Pharmaceuticals, Inc. | 1 | $22 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $19 |
| Eyevance Pharmaceuticals LLC | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Iluvien$16,855
- YUTIQ$1,620
- MiSight Contact Lens$500
- VABYSMO$245
- OZURDEX$149
- LenSx$142
- OPMI Lumera$134
- CIRRUS HD-OCT$118
How this compares
$22,603 in reported general payments places this provider in the 90th percentile of 481 ophthalmology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ProlensaBromfenac Sodium | 63 | $22,147 |
| Prednisolone Acetate | 171 | $8,690 |
| Bromfenac Sodium | 33 | $5,246 |
| CombiganBrimonidine Tartrate/Timolol | 17 | $4,887 |
| IlevroNepafenac | 13 | $4,762 |
| Polymyxin B Sul-TrimethoprimPolymyxin B Sulf/Trimethoprim | 101 | $667 |
| Brimonidine Tartrate | 11 | $591 |
| MoxifloxacinMoxifloxacin Hcl | 20 | $408 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 12 | $175 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa | $19 | $22,14763 claims |
| AbbVieCombigan | $420 | $4,88717 claims |
| NovartisIlevro | $232 | $4,76213 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 481 ophthalmology providers in Georgia.
Other ophthalmology in Sandy Springs
- Dana WallaceSandy Springs$27K
- Robert BlasbergSandy Springs$14K
- Gagan SawhneyAtlanta$582K
- Lawrence WoodardAtlanta$578K
- Stephanie VanderveldtAtlanta$384K
- Steven YehAtlanta$289K
- Jack ChapmanGainesville$244K
- Gregory LeeCumming$214K
- Puneet PandaMarietta$185K
- Jeffrey TranSuwanee$150K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.